Cellectar Biosciences (CLRB) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Pluri (PLUR) over the past year, losing 70.7% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -99.5% for CLRB. Cellectar Biosciences is the larger company by market cap ($13.2 million vs $12.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | PLUR |
|---|---|---|
| Share price | $1.40 | $1.00 |
| Market cap | $13.23M | $12.61M |
| 1-day change | -7.28% | -3.85% |
| YTD return | -52.54% | -66.56% |
| 1-year return | -70.71% | -75.49% |
| 5-year return | -99.49% | -95.23% |
| EPS (TTM) | $-3.46 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $4.87 |
| 52-week low | $1.36 | $0.85 |
| Distance from 52-week high | -72.39% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +721.43% | — |
| Average volume | 61.52K | 25.99K |
| Shares outstanding | 9.45M | 12.61M |
| Employees | 11 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
CLRB vs PLUR FAQ
Which is bigger, Cellectar Biosciences or Pluri?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.23M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, CLRB or PLUR?
CLRB returned -70.71% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.